CeriBell (NASDAQ:CBLL) Releases Earnings Results

CeriBell (NASDAQ:CBLL) issued its quarterly earnings data on Monday. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.04), FiscalAI reports. The firm had revenue of $28.10 million for the quarter, compared to the consensus estimate of $27.28 million. CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%.

Here are the key takeaways from CeriBell’s conference call:

• Q2 revenue rose 33% year over year to $28.1 million, accelerating from 29% growth in Q1, while the active account base increased by 32 to 712. Management cited strong same-store utilization and expects 2026 revenue of $114 million-$117 million, up from prior guidance of $112 million-$116 million.
• Gross margin reached a record 92%, helped by a $1.6 million tariff refund; excluding the refund, margin was still 89%. Ceribell expects margins to remain in the high-80% range, supported by supply-chain savings and expanded manufacturing in Vietnam.
• Ceribell plans to commercially launch its Delirium monitoring solution in Q4 2026 after favorable pilot feedback and CMS approval of an NTAP providing up to $2,171 in incremental reimbursement per qualified patient. Neonatal and pediatric products also received early purchase orders, although management expects these newer offerings to contribute more meaningfully in 2027.
• Operating expenses increased 37% year over year to $45.9 million, contributing to a net loss of $19.3 million, or $0.51 per share. The company continues to reinvest heavily in sales, R&D and platform development, and has not yet specified when it will achieve cash-flow breakeven.
• The company received FDA clearances for artifact-reduction and epileptiform-abnormality algorithms, as well as components of a next-generation hardware platform designed for video, ECG, longer-duration monitoring and full-montage EEG. Limited releases are planned before a broader 2027 launch, which management views as a potential expansion into additional patient populations and markets.

CeriBell Stock Up 2.6%

Shares of NASDAQ CBLL traded up $0.49 during mid-day trading on Monday, hitting $19.30. 424,065 shares of the stock traded hands, compared to its average volume of 331,128. The company has a market cap of $732.24 million, a price-to-earnings ratio of -11.84 and a beta of 0.81. The stock has a fifty day moving average price of $18.52 and a 200-day moving average price of $19.09. CeriBell has a 52 week low of $10.85 and a 52 week high of $24.33. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.01 and a current ratio of 10.44.

Insider Buying and Selling at CeriBell

In other news, CTO Raymond Woo sold 1,966 shares of the company’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $18.00, for a total value of $35,388.00. Following the sale, the chief technology officer directly owned 195,682 shares of the company’s stock, valued at $3,522,276. This represents a 0.99% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Xingjuan Chao sold 39,000 shares of the stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $19.90, for a total transaction of $776,100.00. Following the completion of the transaction, the chief executive officer owned 802,317 shares of the company’s stock, valued at approximately $15,966,108.30. The trade was a 4.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 300,685 shares of company stock valued at $5,935,326. Company insiders own 17.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd increased its holdings in shares of CeriBell by 3,971.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after acquiring an additional 1,231 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in CeriBell during the 3rd quarter valued at about $33,000. Tower Research Capital LLC TRC raised its holdings in CeriBell by 353.8% in the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after buying an additional 1,801 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in shares of CeriBell by 41.4% in the fourth quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock worth $64,000 after buying an additional 854 shares in the last quarter. Finally, Sherbrooke Park Advisers LLC bought a new stake in shares of CeriBell during the third quarter valued at approximately $135,000.

Analyst Upgrades and Downgrades

CBLL has been the subject of several research analyst reports. Weiss Ratings cut CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 14th. Canaccord Genuity Group dropped their price target on CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $22.20.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.